Compare BioNano Genomics Inc (BNGO) vs Figs Inc (FIGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Figs Inc — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while Figs Inc trades at $14.15 (market cap $2.37B). The key difference: Figs Inc is far larger — about 173.5× BioNano Genomics Inc's market cap, and Figs Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | FIGS | |
|---|---|---|
Market Cap | $13.66M | $2.37B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.92 | $17.12 |
52-Week Low | $1.06 | $6.57 |
Enterprise Value | $16.26M | $2.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
FIGS stock trades at $14.50, up 0.76% today, with strong technical momentum and bullish moving averages. Recent Q2 2026 earnings beat expectations with $0.11 EPS and 29% revenue growth, leading to a raised 2026 outlook. The company maintains a high gross margin of 68.91% but faces valuation concerns with a P/E of 43.24. Analyst sentiment is positive with a $19.50 consensus price target.
Outlook remains favorable due to accelerating revenue growth and margin expansion, though the rich valuation and execution risks in H2 2026 pose challenges. Institutional buying and a $100 million share buyback program support bullish sentiment, but investors should weigh premium multiples against growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →
